BioCentury
ARTICLE | Clinical News

Elafin: Completed Phase II enrollment

November 18, 2013 8:00 AM UTC

Proteo completed enrollment of 87 patients who are undergoing coronary bypass surgery in the double-blind, placebo-controlled, U.K. Phase II EMPIRE trial evaluating intraoperative Elafin. Proteo also said it completed a sub-study in which 10 healthy volunteers received an MRI scan, a Feraheme ferumoxytol infusion and a second MRI scan at 24 hours. The company said the study would aid in the interpretation of MRI scans in patients from EMPIRE. Medical Research Council (MRC) and Chest Heart & Stroke Scotland (CHSS) are providing funding for the trial. The compound is also in Phase II testing to prevent acute organ rejection and chronic graft injury in kidney transplantation patients and has completed Phase II testing to treat inflammation following esophagectomy for esophagus carcinoma. ...